News articles

This summer we’ve been pleased to welcome Rutendo Mupfumi from the University of Plymouth to the Amprologix lab. As part of her Biomedical Sciences degree, Rutendo Mupfumi has joined the team to gain hands-on experience in a biotech research environment and see how discoveries in the lab can be turned into meaningful solutions that make […]

Amprologix joins a global network of innovators We're proud to announce that Amprologix is one of the 103 finalists selected to participate in the MassChallenge Switzerland & UK Accelerator Programme 2025, chosen from a pool of 1,527 high-potential startups worldwide. This milestone places Amprologix among a global community of science-driven innovators who are committed to […]

Mat Upton, CSO, presented the latest results from ongoing research at ESCMID Global 2025. ESCMID Global 2025 - the Congress of the European Society of Clinical Microbiology and Infectious Diseases - ran from April 11-15 in Vienna, and was attended by an audience of leading experts in infectious diseases and clinical microbiology. Amprologix presented results from […]

Mat Upton, CSO, presented new data at the 9th AMR conference in Basel on 25th February. It was suggested that probably half the global antimicrobial R&D activity was represented by attendees in the room. In a recent robust skin infection model with MRSA strain USA300, data demonstrate that a single daily dose of lead antibiotic […]

Amprologix will be attending the Investival Showcase in London on 18th November 2024 Amprologix will be attending the Investival Showcase in London on 18th November 2024. We look forward to meeting industry partners and investors who share our passion for developing new treatments to combat the rising global threat from antimicrobial resistance, including superbugs like MRSA and VRE.  For […]

Amprologix files the first of a new series of patents protecting novel molecular structures for the treatment of bacterial infections. July 2024 Amprologix has filed its first patent in a series aimed at developing novel molecular structures for the treatment of bacterial infections. This significant milestone stems from discoveries made by Amprologix's proprietary AI “discovery […]

Innovate UK has awarded Amprologix £1M of Biomedical Catalyst funding to continue the Tobraderm project 1st March 2024 Amprologix is delighted to receive confirmation of its success in securing a £1M Biomedical Catalyst award from Innovate UK for its Tobraderm project. The project will advance the company’s NI01 lead compound through late-preclinical testing for common […]

October 2022 CSO Mat Upton joined 19 other start-ups that were selected from 700 applicants for a place at the Qatar Foundation WISH meeting on 4-6th October 2022.

April 2022 Gordon Barker, Amprologix CEO was selected to present our innovative antibiotic development approach at the Start-ups Session (https://amr-conference.com/start-ups-amr-conference-pitching-session/). The session, sponsored by INCATE and partners, was watched by potential investors and funders and included SMEs developing novel therapies through to vaccines and diagnostics.

January 2022 Amprologix and RefLab ApS (Copenhagen, Denmark) have collaborated on a project using an ex vivo human skin microdialysis model (below) to test pseudo-allergic reactions in the skin, without using animal models.